MedCAD to 3D-Print All Titanium Products
All metal MedCAD products, including AccuPlate plates and AccuShape Ti cranioplasty products, will now be fully converted to 3D titanium...
Apr 25, 2025,
MedCAD to 3D-Print All Titanium Products
Seikagaku and Ono Collaborate on Gel-One
The companies entered an agreement to codevelop and market Gel-One hyaluronate injection for the treatment of osteoarthritis in Japan....
Apr 25, 2025,
Xtant Medical Launches Trivium Advanced Bone Graft
Engineered with PureLoc Fiber Technology, Trivium combines synergistic elements intended to elevate performance in structure, handling, and biological activity....
Apr 24, 2025,
CGBIO Gains Approval for NOVOSIS Putty Trial
The bone graft incorporating rhBMP-2 received FDA Investigational Device Exemption approval for a pivotal clinical trial in spinal fusion....
Apr 24, 2025,
Enrollment Begins for BioPoly Partial Resurfacing Knee Implant Study
Unlike traditional metal, BioPoly material reduces wear and eliminates issues related to metal sensitivity or allergies....
Apr 23, 2025,
ATEC Launches PTP Corpectomy Lateral Approach Surgery
Prone TransPsoas Corpectomy marks the continued evolution of ATEC’s PTP surgical approach for the thoracolumbar spine....
Apr 22, 2025,
Augmedics Hits Milestone with xvision Spine System
The 10,000 patient milestone comes as Augmedics initiates U.S. commercial launch of its CT-Fluoro registration method....
Apr 22, 2025,
Hy2Care to Launch US Trial of CartRevive Hydrogel
The company received Investigational Device Exemption approval to evaluate the implant in the repair of knee cartilage injuries....
Apr 22, 2025,
What We’re Watching: 2025 First Quarter Earnings Results
A look at how the market's 2024 finish, resurgent M&A volume and the potential impact of tariffs on the orthopedic...
Apr 22, 2025,
Personalized Solutions Bear Value in Orthopedics
Materialise's CEO says surgeons and industry see advantages with patient-specific instrumentation and implants and pre-operative planning....
Apr 22, 2025,
Loading new posts...
No more posts
